Gynecologic Disorders - USMLE Step 2

SECTION 1

Historical Context & Motivation

The systematic study of gynecologic disorders has evolved dramatically over several centuries, progressing from rudimentary anatomical observations to the sophisticated molecular and imaging-based approaches used in modern clinical practice. Understanding this historical trajectory is essential for appreciating why certain diagnostic and therapeutic paradigms exist today. Early physicians often conflated gynecologic symptoms with systemic or psychiatric illness, and it was not until the development of anesthesia, antisepsis, and refined surgical technique that gynecologic surgery became viable. The twentieth century brought transformative advances in hormonal physiology, cytologic screening, and minimally invasive surgery that continue to shape contemporary management of conditions ranging from endometriosis and uterine leiomyomata to cervical neoplasia and ovarian malignancy.

1809 • First Ovariotomy

Ephraim McDowell performed the first successful surgical removal of an ovarian tumor without anesthesia, establishing that abdominal surgery for gynecologic disease was survivable and launching the era of operative gynecology.

1928 • Papanicolaou Smear Developed

Georgios Papanicolaou described exfoliative cervical cytology, enabling early detection of cervical dysplasia and carcinoma. The Pap smear became the cornerstone of cervical cancer screening worldwide.

1960 • Oral Contraceptive Pill Approved

FDA approval of the combined oral contraceptive pill revolutionized hormonal management of gynecologic disorders including dysmenorrhea, endometriosis, and abnormal uterine bleeding, in addition to its contraceptive indication.

1987 • Laparoscopic Hysterectomy

Harry Reich performed the first laparoscopic hysterectomy, inaugurating the era of minimally invasive gynecologic surgery and shifting treatment paradigms for fibroids, endometriosis, and gynecologic cancers.

2006 • HPV Vaccine Introduced

Gardasil, the first vaccine against human papillomavirus (HPV), was approved, marking a paradigm shift toward primary prevention of cervical, vulvar, and vaginal neoplasia.

These milestones illustrate a central theme: the progression from empirical observation to evidence-based, pathophysiology-driven management. For the USMLE Step 2 examination, the critical question is not merely what a gynecologic disorder is, but rather how its clinical presentation, risk factors, and pathologic findings guide appropriate diagnostic evaluation and treatment selection. The sections that follow will build this clinical reasoning framework systematically.

SECTION 2

Core Principles & Definitions

A structured approach to gynecologic disorders requires understanding several foundational concepts that recur across pathologies. These principles allow the clinician to organize a differential diagnosis efficiently, prioritize investigations, and select management strategies that align with patient goals and clinical severity. The following core ideas underpin the evaluation of virtually every gynecologic complaint encountered on the wards and on board examinations.

Abnormal Uterine Bleeding (AUB)

Classified by the PALM-COEIN system: Polyp, Adenomyosis, Leiomyoma, Malignancy/hyperplasia (structural) and Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified (non-structural). This mnemonic is the FIGO-endorsed framework.

Estrogen-Dependent Pathology

Many gynecologic disorders—including endometriosis, leiomyomata, and endometrial hyperplasia—are driven by unopposed or excess estrogen stimulation. Recognizing estrogen dependence guides both pharmacologic (GnRH agonists, progestins) and surgical management.

Age-Stratified Differential Diagnosis

The differential for a gynecologic complaint varies markedly by age. Postmenopausal bleeding mandates endometrial sampling to exclude malignancy, while adolescent AUB is most commonly anovulatory. Always stratify by reproductive stage.

Pelvic Pain: Acute vs. Chronic

Acute pelvic pain requires emergent evaluation (ectopic pregnancy, ovarian torsion, tubo-ovarian abscess), whereas chronic pelvic pain (>6 months) is often multifactorial—endometriosis, adenomyosis, adhesive disease, and functional pain syndromes.

Screening & Prevention

Cervical cancer is a screening success story (Pap + HPV co-testing). Ovarian cancer lacks an effective screening tool for the general population. Understanding which conditions are screenable and which are not is essential for clinical decision-making.

✦

KEY TAKEAWAY

Think of the gynecologic evaluation like triaging a multi-alarm fire station: the dispatcher (your clinical history) must first determine whether the alarm is structural (a physical lesion—polyp, fibroid, mass) or functional (a hormonal or systemic process—anovulation, coagulopathy). This structural versus non-structural dichotomy, formalized in PALM-COEIN, is the single most useful organizing principle for approaching abnormal uterine bleeding and, by extension, most gynecologic complaints.

SECTION 3

Visual Explanation — Gynecologic Disorder Differential by Anatomy

This anatomic map organizes common gynecologic disorders by their site of origin within the female reproductive tract. Note how the uterine body harbors the greatest diversity of pathology, reflecting the estrogen-responsive endometrium and myometrium. The fallopian tube box includes high-grade serous carcinoma (HGSC), now believed to originate from tubal epithelium in most cases.

Organizing gynecologic disorders by anatomic site provides an intuitive framework for developing differential diagnoses. When a patient presents with pelvic pain, the clinician can mentally move through the tract from external (vulvar) to internal (adnexal) structures, considering the pathologies most likely at each level. For board examinations, pay particular attention to the uterine and ovarian compartments, as these generate the highest volume of clinical questions. Also note that the cervical transformation zone is a critical concept: it is the junction of squamous and columnar epithelium where HPV-related dysplasia originates, and its position changes with age and hormonal status, influencing Pap smear adequacy.

SECTION 4

Pathophysiologic Mechanisms

Hormonal Mechanisms in Estrogen-Dependent Disorders

The hypothalamic-pituitary-ovarian (HPO) axis governs the cyclical production of estrogen and progesterone that drives endometrial proliferation and secretory transformation. Disruption of this axis at any level can produce gynecologic disease. In polycystic ovary syndrome (PCOS), chronic anovulation leads to unopposed estrogen stimulation of the endometrium, increasing the risk of endometrial hyperplasia and, ultimately, type I endometrial carcinoma. Excess peripheral conversion of androgens to estrone in adipose tissue further amplifies this risk in obese patients. Conversely, in endometriosis, ectopic endometrial-like tissue responds to cyclical hormonal stimulation, generating an inflammatory milieu with prostaglandin overproduction, neoangiogenesis, and fibrosis that account for the characteristic dysmenorrhea, dyspareunia, and dyschezia seen clinically.

Infectious and Oncogenic Mechanisms

Cervical carcinogenesis provides a paradigmatic example of viral oncogenesis. High-risk HPV types 16 and 18 integrate their DNA into the host genome of cervical epithelial cells, producing oncoproteins E6 and E7. E6 targets p53 for proteasomal degradation, disabling apoptotic pathways, while E7 inactivates the retinoblastoma (Rb) tumor suppressor, allowing unchecked cell cycle progression. This dual-hit mechanism drives the stepwise progression from normal epithelium to CIN I → CIN II → CIN III → invasive squamous cell carcinoma. The process typically takes 10–20 years, which is why screening intervals can be extended safely to every 3–5 years with current co-testing guidelines.

The upper panel illustrates the stepwise progression from normal cervical epithelium through CIN stages to invasive carcinoma, with the molecular events (E6/p53, E7/Rb) highlighted. The timeline bar below approximates the duration of each phase. The lower panel maps management strategies to each stage, from primary prevention with HPV vaccination through LEEP for high-grade dysplasia and chemoradiation for invasive disease.

Pelvic Inflammatory Disease Pathogenesis

Pelvic inflammatory disease (PID) results from ascending infection, typically polymicrobial, from the lower genital tract through the cervix into the endometrium, fallopian tubes, and peritoneal cavity. Neisseria gonorrhoeae and Chlamydia trachomatis are the most commonly identified pathogens, although anaerobes, facultative gram-negative rods, and genital mycoplasmas frequently participate. The clinical hallmark is cervical motion tenderness accompanied by uterine or adnexal tenderness in a sexually active woman. Sequelae include tubo-ovarian abscess (TOA), Fitz-Hugh-Curtis syndrome (perihepatitis), tubal factor infertility, and increased risk of ectopic pregnancy. The CDC recommends a low threshold for empiric treatment because even subclinical PID can produce irreversible tubal damage.

SECTION 5

Detailed Classification of Major Gynecologic Disorders

Abnormal Uterine Bleeding — PALM-COEIN Classification

Category	Etiology	Key Features	Diagnosis
P — Polyp	Endometrial or endocervical polyp	Intermenstrual bleeding; postmenopausal bleeding	Transvaginal US / saline infusion sonohysterography; hysteroscopy with polypectomy
A — Adenomyosis	Endometrial glands within myometrium	Menorrhagia, dysmenorrhea, diffusely enlarged 'boggy' uterus	MRI (junctional zone >12 mm); definitive dx on hysterectomy specimen
L — Leiomyoma	Benign smooth muscle tumor	Heavy menstrual bleeding (esp. submucosal); bulk symptoms; firm, irregular uterus	Pelvic US; classify by FIGO subtype (0–8); MRI for surgical planning
M — Malignancy	Endometrial carcinoma or hyperplasia	Postmenopausal bleeding; abnormal glandular cells on Pap	Endometrial biopsy (Pipelle); consider D&C if insufficient sample
C — Coagulopathy	von Willebrand disease; platelet disorders; anticoagulation	Heavy menses since menarche; easy bruising; family history	CBC, PT/INR, PTT, vWF antigen/activity, factor levels
O — Ovulatory	PCOS; hypothalamic amenorrhea; thyroid disorders	Irregular, unpredictable bleeding; cycles <21 or >35 days	TSH, prolactin, FSH/LH, androgens; progesterone challenge test
E — Endometrial	Primary disorder of endometrial hemostasis	Regular but heavy menses; normal imaging and labs	Diagnosis of exclusion; endometrial biopsy to rule out other causes
I — Iatrogenic	IUDs, hormonal contraceptives, anticoagulants	Bleeding temporally related to medication/device use	Medication review; removal of offending agent
N — Not classified	AV malformations, cesarean scar defect, chronic endometritis	Variable; does not fit neatly into other categories	Varies by suspected etiology

FIGO PALM-COEIN Classification for Abnormal Uterine Bleeding

Ovarian Mass Classification

Ovarian masses are broadly divided into functional (physiologic), benign neoplastic, and malignant categories. Functional cysts (follicular and corpus luteum) are the most common adnexal masses in reproductive-age women and typically resolve within 6–8 weeks. Among benign neoplasms, mature cystic teratomas (dermoid cysts) are the most frequent in young women, while serous cystadenomas predominate in the perimenopausal group. Malignant ovarian tumors are classified as epithelial (most common, ~90% in adults), germ cell (most common in women <20), or sex cord-stromal. Epithelial ovarian cancer is further subdivided into high-grade serous (most common and most lethal), endometrioid, clear cell, mucinous, and low-grade serous subtypes. The risk of malignancy index (RMI) incorporates ultrasound morphology, menopausal status, and CA-125 level to guide surgical triage.

💡

High-Yield Board Tip

A postmenopausal woman with a complex adnexal mass, elevated CA-125, and ascites should be referred to a gynecologic oncologist for surgical staging rather than managed with observation or simple laparoscopic cystectomy. The key clinical scenario is distinguishing benign from malignant masses using the IOTA simple rules or RMI.

SECTION 6

Worked Clinical Example

The following clinical vignette models the step-by-step reasoning process expected for a USMLE Step 2 question involving a gynecologic disorder.

Clinical Vignette: 34-Year-Old Woman with Heavy Menstrual Bleeding and Pelvic Pressure

1
Step 1 — Gather Clinical Data

A 34-year-old G2P2 African American woman presents with progressively heavy menstrual bleeding for the past 12 months, now soaking through a pad every 1–2 hours during menses that last 8 days. She also reports pelvic pressure and urinary frequency. She denies intermenstrual or postcoital bleeding. BMI is 28. On pelvic exam, the uterus is palpably enlarged (approximately 14-week size), firm, and irregular in contour. Adnexa are non-tender.
2
Step 2 — Generate a Differential Diagnosis

Using PALM-COEIN: the enlarged, irregular uterus strongly suggests a structural cause. The top differential includes uterine leiomyomata (L) given the patient's age, race, and exam findings. Adenomyosis (A) is possible but typically produces a diffusely enlarged, globular, tender uterus rather than an irregular one. Endometrial polyp (P) or malignancy (M) are less likely given her age but cannot be excluded without further workup.

Most likely diagnosis: Uterine leiomyomata (fibroids)
3
Step 3 — Order Diagnostic Studies

The initial study is a transvaginal ultrasound (TVUS), which confirms multiple leiomyomata, the largest being a 6 cm submucosal fibroid (FIGO type 1) distorting the endometrial cavity. A CBC reveals hemoglobin of 9.8 g/dL (iron deficiency anemia secondary to chronic blood loss). TSH is normal. Pregnancy test is negative. MRI may be obtained for surgical planning if myomectomy is considered.

TVUS confirms submucosal fibroid; CBC shows iron deficiency anemia
4
Step 4 — Select Management

Management depends on symptom severity, fibroid location, and reproductive goals. This patient desires future fertility. For a symptomatic submucosal fibroid in a woman desiring pregnancy, hysteroscopic myomectomy is the preferred approach. Medical bridging with a GnRH agonist (e.g., leuprolide) for 3 months preoperatively can reduce fibroid volume and improve anemia. Tranexamic acid and iron supplementation address heavy bleeding and anemia in the interim. If she did not desire fertility, hysterectomy would be definitive.

Hysteroscopic myomectomy with preoperative GnRH agonist and iron repletion
5
Step 5 — Counsel on Prognosis & Follow-Up

Recurrence of fibroids after myomectomy occurs in approximately 15–30% of patients within 5 years. Postoperative surveillance includes clinical exams and symptom monitoring. The patient should be counseled that definitive treatment is hysterectomy if fibroids recur and she has completed childbearing. Newer options include uterine artery embolization and radiofrequency ablation, though these may have implications for future fertility.

SECTION 7

Comparing Common Gynecologic Disorders

Board examinations frequently test the ability to distinguish between disorders with overlapping clinical presentations. The following table compares four conditions that commonly present with pelvic pain and/or abnormal uterine bleeding, highlighting the distinguishing features that guide diagnosis.

Feature	Endometriosis	Adenomyosis	Leiomyomata	Endometrial Cancer
Typical Age	25–35 yrs	35–50 yrs (multiparous)	30–50 yrs	Postmenopausal (median 63 yrs)
Pain Pattern	Cyclical dysmenorrhea, dyspareunia, dyschezia	Severe dysmenorrhea with menorrhagia	Pressure symptoms; pain uncommon unless degenerating	Often painless; pain suggests advanced disease
Uterine Exam	Normal size; fixed retroverted uterus; uterosacral nodularity	Diffusely enlarged, globular, boggy, tender	Asymmetrically enlarged, firm, irregular	May be normal or slightly enlarged
Key Imaging	MRI; TVUS may show endometriomas ('chocolate cysts')	MRI: junctional zone >12 mm; TVUS: heterogeneous myometrium	TVUS: well-circumscribed hypoechoic masses with acoustic shadowing	TVUS: thickened endometrial stripe (>4 mm postmenopausal)
Gold Standard Dx	Laparoscopy with biopsy (clinical dx now accepted)	Hysterectomy specimen (pathologic)	Pelvic ultrasound (clinical)	Endometrial biopsy (histologic)
First-Line Tx	NSAIDs + OCP/progestins; GnRH agonist; laparoscopic excision	LNG-IUD; GnRH agonist; definitive: hysterectomy	Depends on symptoms/fertility: observation, myomectomy, UAE, hysterectomy	Total hysterectomy with BSO; staging; adjuvant chemo/radiation per stage

Comparison of Four Common Causes of Pelvic Pain and Abnormal Uterine Bleeding

✦

KEY TAKEAWAY

Think of these four conditions as members of a family sharing the same address (the pelvis) but with distinct personalities. Endometriosis is the wanderer—ectopic tissue causing cyclical pain at distant sites. Adenomyosis is the introvert—endometrial tissue invading inward into the myometrium, producing a symmetrically boggy uterus. Leiomyomata are the builders—discrete, firm masses creating an irregular architecture. Endometrial cancer is the silent threat—often presenting only with painless bleeding, but requiring urgent histologic evaluation. Recognizing each 'personality' by physical exam and imaging is the key to efficient differential diagnosis.

SECTION 8

Connections to Advanced Clinical Concepts

While USMLE Step 2 emphasizes clinical diagnosis and initial management, several gynecologic disorders bridge into advanced subspecialty territory. Understanding these connections reinforces pathophysiologic reasoning and prepares you for clerkship-level and residency-level decision-making.

Step 2 Concept	Advanced Extension	Clinical Relevance
Cervical dysplasia management (LEEP, CKC)	Sentinel lymph node mapping in early cervical cancer; fertility-sparing trachelectomy	Expanding surgical options for young patients with early-stage cervical cancer
Endometriosis diagnosis and hormonal suppression	Deep infiltrating endometriosis (DIE); elagolix (oral GnRH antagonist); ART for endometriosis-related infertility	Newer pharmacologic agents and reproductive technology expanding treatment options
Endometrial cancer staging (FIGO surgical)	Molecular classification (POLE, MSI-H, p53-mutant); immune checkpoint inhibitors (pembrolizumab + lenvatinib)	Genomic profiling now guides adjuvant therapy decisions in advanced endometrial cancer
Ovarian mass evaluation (CA-125, US)	BRCA1/2 and homologous recombination deficiency; PARP inhibitors (olaparib); HIPEC for peritoneal carcinomatosis	Genetic testing and targeted therapy have transformed survival in advanced epithelial ovarian cancer
PCOS diagnosis (Rotterdam criteria)	Metabolic syndrome, insulin resistance, cardiovascular risk stratification; anti-Müllerian hormone (AMH) as diagnostic adjunct	PCOS is increasingly recognized as a systemic metabolic disorder beyond reproductive endocrinology

Step 2 Foundations and Their Advanced Clinical Extensions

The advent of molecular classification in endometrial cancer (The Cancer Genome Atlas, 2013) represents a paradigm shift from purely histopathologic staging toward genomics-guided treatment. Similarly, the recognition that most high-grade serous ovarian cancers harbor TP53 mutations and often arise from fallopian tube epithelium has fundamentally changed risk-reduction surgery recommendations: risk-reducing salpingo-oophorectomy is now standard for BRCA carriers by age 35–40. These advanced concepts are not heavily tested on Step 2 but provide critical context for understanding the direction of gynecologic oncology and the rationale behind current screening and prevention strategies.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 28-year-old nulliparous woman presents with severe dysmenorrhea, deep dyspareunia, and dyschezia. On bimanual exam, her uterus is fixed in retroversion and tender nodularity is palpated along the uterosacral ligaments. What is the most likely diagnosis, and what is the proposed pathophysiologic mechanism that best explains the ectopic tissue implants?

Show answer

The most likely diagnosis is endometriosis. The leading pathophysiologic theory is Sampson's theory of retrograde menstruation, which posits that endometrial fragments reflux through the fallopian tubes during menses and implant on peritoneal surfaces. The triad of cyclical dysmenorrhea, dyspareunia, and dyschezia is classic for endometriosis involving the posterior cul-de-sac and rectovaginal septum. The fixed, retroverted uterus and uterosacral nodularity reflect adhesive disease from chronic inflammation caused by cyclical bleeding of the ectopic endometrial implants.

Question 2: BASIC CALCULATION

A 58-year-old postmenopausal woman presents with vaginal bleeding. Transvaginal ultrasound reveals an endometrial thickness of 8 mm. The threshold for endometrial biopsy in a postmenopausal woman with bleeding is an endometrial stripe >4 mm. What is the next best step in management, and what are the two most important histologic diagnoses to exclude?

Show answer

The next best step is an office endometrial biopsy (Pipelle sampling). At 8 mm, the endometrial stripe exceeds the 4 mm threshold that, in the setting of postmenopausal bleeding, has a negative predictive value exceeding 99% for endometrial cancer. The two most important diagnoses to exclude are endometrial hyperplasia with atypia (a premalignant condition) and endometrial carcinoma (most commonly Type I endometrioid adenocarcinoma). If the Pipelle sample is insufficient or non-diagnostic, dilation and curettage under hysteroscopic guidance should be performed.

Question 3: INTERMEDIATE

A 22-year-old sexually active woman presents with lower abdominal pain, fever (38.5°C), purulent vaginal discharge, and bilateral adnexal tenderness. Cervical motion tenderness is present. She has a copper IUD placed 3 weeks ago. β-hCG is negative. What is the diagnosis? What empiric antibiotic regimen should be initiated? Should the IUD be removed?

Show answer

The diagnosis is pelvic inflammatory disease (PID), meeting the CDC minimum criteria of cervical motion tenderness, uterine tenderness, and adnexal tenderness in a sexually active woman. The CDC-recommended outpatient regimen is IM ceftriaxone 500 mg single dose plus oral doxycycline 100 mg BID for 14 days, with or without oral metronidazole 500 mg BID for 14 days for anaerobic coverage. Regarding the IUD, current CDC guidelines recommend that the IUD may remain in place if the patient responds to antibiotics within 48–72 hours, as IUD removal has not been shown to improve outcomes in mild-to-moderate PID. However, if there is no clinical improvement within 72 hours, IUD removal and possible inpatient IV antibiotics should be considered.

Question 4: APPLIED

A 45-year-old G3P3 woman with a BMI of 38, type 2 diabetes, and irregular menses every 2–4 months undergoes an endometrial biopsy that reveals complex endometrial hyperplasia with atypia. She has completed childbearing. Explain the pathophysiologic link between her clinical profile and this diagnosis. What is the recommended definitive management, and what is the approximate risk of concurrent or progression to endometrial carcinoma?

Show answer

This patient's obesity, anovulatory cycles, and diabetes create a state of chronic unopposed estrogen exposure. Adipose tissue aromatase converts adrenal androgens to estrone, which stimulates endometrial proliferation without the counterbalancing effect of progesterone (which requires ovulation to be produced by the corpus luteum). Insulin resistance in PCOS and type 2 diabetes further promotes endometrial proliferation via IGF-1 pathways. Complex atypical hyperplasia carries approximately a 25–30% risk of concurrent undiagnosed endometrial carcinoma and up to 40–50% risk of progression to carcinoma if left untreated. Definitive management in a patient who has completed childbearing is total hysterectomy with bilateral salpingo-oophorectomy and surgical staging if carcinoma is found on final pathology.

Question 5: CRITICAL THINKING

A 16-year-old girl presents with heavy menstrual bleeding since menarche at age 12, with periods lasting 10 days and requiring frequent pad changes. She has a family history of epistaxis in her father. CBC shows Hgb 8.2 g/dL and platelets 220,000. PT and PTT are normal. Construct a diagnostic approach that addresses the most likely etiology in this age group. Discuss why the PALM-COEIN structural causes are less likely, and propose an initial management strategy while awaiting definitive diagnosis.

Show answer

In an adolescent with heavy menstrual bleeding since menarche and a family history of epistaxis, the PALM-COEIN non-structural category 'C' (coagulopathy) is the leading consideration, specifically von Willebrand disease (vWD), which is the most common inherited bleeding disorder and affects up to 13% of women with menorrhagia. Structural causes (polyps, adenomyosis, leiomyomata, malignancy) are exceedingly rare in a 16-year-old without other risk factors. Normal PT and PTT do not exclude vWD, as these tests are insensitive for mild factor deficiencies. The diagnostic workup should include von Willebrand factor antigen, ristocetin cofactor activity (vWF:RCo), factor VIII level, and a PFA-100 closure time. While awaiting results, initial management includes iron supplementation for the anemia (Hgb 8.2 warrants oral or IV iron depending on tolerance), combined oral contraceptive pills to regulate menses and reduce menstrual blood loss, and tranexamic acid during menses as an antifibrinolytic adjunct. If vWD type 1 is confirmed, desmopressin (DDAVP) can be administered prophylactically before procedures or during severe bleeding episodes. This case illustrates the importance of considering coagulopathy in any adolescent with menorrhagia since menarche—a frequently tested concept on USMLE Step 2.

SUMMARY

Gynecologic Disorders — Summary Review

Summary

Gynecologic disorders encompass a broad spectrum of conditions organized most effectively by the PALM-COEIN classification for abnormal uterine bleeding and by anatomic site for broader differential diagnosis. The structural causes—polyps, adenomyosis, leiomyomata, and malignancy—are distinguished from non-structural causes such as coagulopathies, ovulatory dysfunction, and iatrogenic factors through a combination of history, physical examination, pelvic imaging (principally transvaginal ultrasound), and targeted laboratory studies.

Key high-yield principles for Step 2 include: postmenopausal bleeding always requires endometrial biopsy to exclude malignancy; HPV oncoproteins E6 and E7 drive cervical carcinogenesis by disabling p53 and Rb; cervical motion tenderness is the hallmark of PID warranting empiric antibiotics; unopposed estrogen is the unifying risk factor for endometrial hyperplasia and Type I endometrial carcinoma; and management of fibroids, endometriosis, and adenomyosis must be individualized based on symptom severity, patient age, and reproductive goals. Mastering the clinical reasoning framework—history → differential → targeted workup → evidence-based management—is the foundation for answering gynecologic disorder questions on board examinations.